05:44 PM EST, 03/06/2024 (MT Newswires) -- TScan Therapeutics ( TCRX ) filed a shelf registration statement late Wednesday with the US Securities and Exchange Commission covering the potential sale of up to $300 million of securities from time to time in one or more offerings.

The filing covers the company's voting and nonvoting common stock, preferred stock, debt securities, warrants and units.

The company said it plans to use the net proceeds mainly for research and development of its product candidates.

TScan Therapeutics ( TCRX ) shares were down about 2.9% in after-hours activity.

Price: 6.94, Change: -0.21, Percent Change: -2.94